Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative Dentistry (NCT07511959) | Clinical Trial Compass
By InvitationNot Applicable
Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative Dentistry
Poland68 participantsStarted 2026-04
Plain-language summary
The aim of the research is the laboratory assessment of the content as well as the regenerative and anti-inflammatory potential of autologous exosomes (EXO) from platelet-rich plasma, as well as their comparison with other autologous products used in intra-articular injections (PRP, PRF).
The material for the research will be obtained from patients of the Temporomandibular Joint Dysfunction Clinic at the University Dental Center in Wrocław with chronic pain of the temporomandibular joints and/or masticatory muscles and/or chronic disturbances in temporomandibular joint mobility, as well as from healthy individuals.
In the subsequent stages, the biological material will be analyzed under laboratory conditions to compare the composition and biological properties of PRF, PRF and EXO.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* chronic pain of the temporomandibular joints and/or masticatory muscles and/or chronic dysfunction of the temporomandibular joints (lasting more than 3 months, diagnosed based on the standardized, international Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) protocol) - criterion for the study group
* consent to participate in the study - criterion for both groups
* age over 18 years - criterion for both groups
Exclusion Criteria:
* cancer,
* pregnancy
* uncontrolled diabetes
* cardiovascular diseases (platelet dysfunction syndrome, critical thrombocytopenia, hemodynamic instability, sepsis, HGB \< 10 g/dl, platelet count \< 105/µl)
* severe autoimmune diseases
* taking anticoagulants
* active skin lesions at the planned puncture site
* infections, patient undergoing antibiotic therapy, or within 3 weeks of its completion.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Comparison of the number and size of exosomes obtained from the study and control groups
Timeframe: 04.2026 - 12.2027
2
Comparison of the level of cytokines and growth factors in exosomes, PRF and PRP samples obtained from the study and control groups
Timeframe: 04.2026 - 12.2027
3
Comparison of the impact of exosomes, PRF and PRP (from the study and control groups) on the proliferation and migration of human chondrocytes and fibroblasts